肺鳞癌的免疫治疗进展

In recent years, squamous non-small cell lung cancer (NSCLC) didn't progress much in chemotherapy or target therapy. However, immunotherapy has made breakthroughs in treating squamous NSCLC. Immunotherapy includes two main broad classes of immune checkpoint inhibitors and therapeutic vaccines....

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2016
Materias:
肺鳞癌专题
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973414/
https://www.ncbi.nlm.nih.gov/pubmed/27760599
http://dx.doi.org/10.3779/j.issn.1009-3419.2016.10.09
Descripción
Sumario:In recent years, squamous non-small cell lung cancer (NSCLC) didn't progress much in chemotherapy or target therapy. However, immunotherapy has made breakthroughs in treating squamous NSCLC. Immunotherapy includes two main broad classes of immune checkpoint inhibitors and therapeutic vaccines. Immune checkpoint inhibitors, including anti cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) and anti programmed death receptor 1 (PD-1) antibodies, have been tested in the phase Ⅱ/Ⅲ clinical trials and have demonstrated promising outcomes. Immunotherapy will become an important treatment for squamous NSCLC.

Ejemplares similares